Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Recent Phase 3 trial results for Icotrokinra (JNJ-2113), an investigational oral peptide from Johnson & Johnson, have shown the drug’s potential to offer significant relief for patients suffering from ...

Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...

In people with psoriasis, immune cells secrete inflammatory biomarkers that cause the skin to overproduce keratinocytes and create plaques on the skin that are characteristic of plaque psoriasis, ...

The study was conducted among patients with plaque psoriasis affecting special areas such as the scalp, genitals and/or hands ...

Positive, phase 3 data for once-daily JNJ-2113 (icotrokinra) has been announced by Protagonist Therapeutics in collaboration with Johnson & Johnson that demonstrated "significant" skin clearance ...

"Plaque psoriasis often affects patients more severely than can be measured by body surface area alone, particularly for those with manifestations in difficult-to-treat areas like the scalp," she ...

Credit: Getty Images Researchers evaluated the efficacy and safety of deucravacitinib for the treatment of moderate to severe scalp psoriasis. Deucravacitinib was safe and effective for treating ...

Lesions may affect the face, ears, and scalp, but the palms and soles ... Guttate psoriasis may represent the initial stage of chronic plaque-type psoriasis. On resolution, post-inflammatory ...